key: cord-0938460-bg0cw5s6
authors: Yan, Dan; Liu, Xiao-yan; Zhu, Ya-nan; Huang, Li; Dan, Bi-tang; Zhang, Guo-jun; Gao, Yong-hua
title: Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection
date: 2020-03-27
journal: nan
DOI: 10.1101/2020.03.22.20040832
sha: c3e8df89ae8483ad09682ea77f013e9845253b57
doc_id: 938460
cord_uid: bg0cw5s6

Background: The duration of viral shedding is central to guide decisions around isolation precautions and antiviral treatment. However, studies about risk factors associated with prolonged SARS-CoV-2 shedding and the potential impact of Lopinavir/Ritonavir (LPV/r) treatment remain scarce. Methods: In this retrospective study, data were collected from all SARS-CoV-2 infected patients who were admitted to isolation wards and had RT-PCR conversion at the NO.3 People's hospital of Hubei province between 31 January and 09 March 2020. We compared clinical features and SARS-CoV-2 RNA shedding between patients with LPV/r treatment and those without. Logistic regression analysis was employed to evaluate risk factors associated with prolonged viral shedding. Results: Of 120 patients, the median age was 52 years, 54 (45%) were male and 78 (65%) received LPV/r treatment. The median duration of SARS-CoV-2 RNA detection from symptom onset was 23 days (IQR, 18-32 days). Older age (odd ratio [OR] 1.03, 95% confidence interval [CI] 1.00-1.05, p=0.03) and lack of LPV/r treatment (OR 2.42, 95% CI 1.10-5.36, p=0.029) were independent risk factors for prolonged SARS-CoV-2 RNA shedding in multivariate logistic regression analysis. The median duration of viral shedding was shorter in the LPV/r treatment group (n=78) than that in no LPV/r treatment group (n=42) (median, 22 days vs. 28.5 days, p=0.02). Only earlier administration of LPV/r treatment (≤10 days from symptom onset) could shorten the duration of viral shedding. Conclusions: Older age and lack of LPV/r treatment were independently associated with prolonged SARS-CoV-2 RNA shedding in patients with COVID-19. Earlier administration of LPV/r treatment could shorten viral shedding.

Since first case reported in Wuhan in December, a novel coronavirus, termed SARS-CoV-2, has rapidly spread through other regions of China and the whole world subsequently with 209,839 cases and 8,778 deaths globally as of 19 March 2020 [1] [2] [3] [4] [5] .

The World Health Organization (WHO) has therefore declared that SARS-CoV-2 has caused a pandemic at 12 March 2020 in view of outbreak of SARS-CoV-2 outside of China. The spectrum of SARS-CoV-2 infection (designated as coronavirus disease 2019 ) ranging from asymptomatic to fatal pneumonia occurred more frequently in patients with underlying conditions [2] [3] [4] [5] [6] [7] . To date, there is no vaccine and proven therapy to prevent and treat this deadly virus.

In past two months, there are numerous epidemiological and clinical reports on COVID-19 [2] [3] [4] [5] [6] [7] . However, few studies have evaluated the duration of viral shedding which has important implications for guiding decisions around isolation precautions and antiviral treatment in patients with confirmed COVID-19 [7, 8] . Factors associated with prolonged duration of viral shedding are totally unclear. One recent randomized controlled trial showed that Lopinavir/Ritonavir (LPV/r) treatment could not provide incremental benefits, including viral shedding, beyond standard care in hospitalized severely ill patients with COVID-19 [9] . But a post hoc subgroup analysis found that earlier administration of LPV/r treatment could accelerate clinical recovery and reduce mortality [9] . Therefore, it remains crucial to determine whether adding LPV/r treatment impacts the duration of SARS-CoV-2 RNA shedding in non-critically ill patients and whether earlier administration of LPV/r could shorten the duration of viral shedding.

Thus, the study aims to assess the risk factors associated with prolonged viral shedding and the potential impact of earlier administration of LPV/r treatment on the duration of viral shedding in hospitalized non-critically ill patients with SARS-CoV-2 infection during 31 January to 09 March 2020.

This retrospective study included all patients who were laboratory-confirmed SARS-CoV-2 infection and had the available RNA viral data to estimate the duration of viral shedding admitted to the NO.3 People's Hospital of Hubei province between 31 January 2020 and 9 March 2020, which was one of designated hospital during the outbreak of SARS-CoV-2 in Wuhan. Demographic, clinical, laboratory, treatment and successive viral data were extracted from electronic medical records using a standardized data collection sheet modified based on the WHO/International Severe Acute Respiratory and Emerging Infection Consortium case record form. We assessed severity of illness according to the Chinese management guideline for COVID-19 (version 6.0) [10] . We collected the dose and duration of LPV/r treatment. All data were double checked by two physicians (DY and XYL) with discrepancy resolved by consensus discussion (DY, XYL and YHG). The institutional review board of the NO.3

People's Hospital of Hubei province approved the study, and patient-level informed consent were waived.

Laboratory identification of SARS-CoV-2 infection was made at Jinyintan Hospital and the NO.3 People's hospital of Hubei province by real-time reverse transcriptionpolymerase chain reaction (RT-PCR) assay using the same method described in previous studies with detection reagents provided by the local Center for Disease Control (CDC) [2, 3] . After admission, throat-swab specimens were collected and sent to re-detect SARS-CoV-2 RNA by real-time PCR every other day after symptom remission (including fever, cough and dyspnea etc.), and the quantitative viral data was not available. The duration of viral shedding was defined as the date of symptom onset to the day when SARS-CoV-2 was undetectable from two consecutive throat-swab specimens, without a positive test afterward. Corticosteroid treatment was referred to administer a dose equivalent to 25 mg or more of methylprednisolone per day during hospitalization. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 27, 2020. . https://doi.org/10.1101/2020.03.22.20040832 doi: medRxiv preprint LPV/r treatment LPV/r (400mg and 100mg, orally, twice daily) was administered to confirmed cases based on the discretion of the physicians at every isolation ward. The treatment duration was 10 days or more with according to the recommendations by Chinese management guideline for COVID-19 (version 6.0) [10] . The exposure of LPV/r was defined as receiving at least one dosage of drug.

Data were presented as mean (standard deviation, SD) or median (interquartile range, IQR) or number (percentage) as appropriate. We employed the Student's t test, ANOVA test, or their corresponding non-parametrical tests for continuous variables, and the X 2 test or Fisher exact test for categorized variables for the comparisons of groups as needed. Univariate and adjusted multivariate logistic regression analysis were used to identify risk factors associated with prolonged duration of SARS-CoV-2 RNA shedding. The prolonged viral shedding was defined as the duration of SARS-CoV-2 RNA shedding longer than 23 days. The cut-off was determined a priori based on median duration of viral shedding in our study. Outcomes were defined as initial time of symptom onset to SARS-CoV-2 RNA negativity, which required undetectable RNA from two consecutive throat-swab specimens and without a positive test afterward.

Variables used for analysis of prolonged viral shedding included age, sex, smoking, comorbidities (including diabetes, hypertension and cardiac disease), corticosteroid treatment and LPV/R treatment. All statistical analysis was performed using the SPSS version 22.0 software (IBM). A two-tailed P value of <0.05 was regarded as statistically significant.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

From 31 January 2020 to 9 March 2020, 168 confirmed cases admitted to our hospital.

As of 9 March 2020, a total of 48 patients (28.6%) were still tested positive for SARS-CoV-2 RNA, of whom 8 patients (4.8%) have died. 120 (71.4%) had resolution of SARS-CoV-2 shedding and were included in the final analysis. All the respiratory specimens tested were from throat-swabs. Regarding laboratory results (data available for 119 patients), white blood cell was below the normal range in 27 (22.7%) and above the normal range in 10 (8.4%). 29 (24.3%) had lymphocyte below 0.8×10 9 /liter. The proportion of abnormal platelet count, creatine level and AST were 5.9%, 3.4% and 27.7%, respectively. 54 patients (45%) received systemic corticosteroid treatment and 78 (65%) received LPV/r treatment. The median hospital length of stay was 21 days.

The median duration of SARS-CoV-2 RNA shedding was 23 days (IQR 18-32 days). Only The median duration of SARS-CoV-2 RNA shedding >23 days was defined as prolonged viral shedding in the current study. Table E1 showed the main characteristics between All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in and lack of LPV/r treatment (OR 2.42, 95% CI 1.10-5.36, p=0.029) were the independent risk factors associated with prolonged SARS-CoV-2 shedding (Table 2) .

However, comorbidities (including current smoker, hypertension, diabetes, cardiac disease) and administration of systemic corticosteroid were not associated with prolonged viral shedding.

Of the 120 patients, 78 patients (65%) were administrated with LPV/r treatment.

Patients receiving LPV/r treatment and those not receiving LPV/r treatment were similar in most baseline characteristics (Table 3) . However, patients receiving LPV/r treatment were more likely to be categorized as severe COVID-19 and have a higher ratio of lymphocyte count <0.8×10 9 /liter than those without LPV/r treatment. LPV/r therapy was started at a median of 10 days (IQR 7-13) from symptom onset. Of 78 patients who received LPV/r treatment, 16 patients (20.5%), 46 (59%) and 64 (82.1%) were initially administered LPV/r treatment within 5 days, 10 days and 15 days from symptom onset, respectively. 7 patients (8.9%) started to administer LPV/r treatment after 20 days (figure 2A). The median duration of LPV/r treatment was 10 days (IQR 9-10). 61 patients (78.2%) received ≥10 days LRV/r treatment. The median duration of SARS-CoV-2 shedding in LPV/r treatment group was 22 days (IQR 18-29), which was shorter than that in no LPV/r treatment group (28.5 days, IQR 19.5-38) (p=0.02).

Patients who started LPV/r treatment within 10 days from symptom onset had a shorter duration of SARS-CoV-2 RNA shedding than other patients who began after 10 days (median 19 days vs. 27.5 days, p<0.001). In contrast, the median duration of viral shedding did not differ between patients who initiated LPV/r treatment from symptom onset >10 days and patients who did not receive LPV/r treatment (median 27.5 days vs. 28.5 days, p=0.86) (figure 2B). All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Viral shedding is commonly used as a proxy measure for infectivity, identification of the duration of viral shedding is central to inform control policies and antiviral treatment in patients with COVID-19. In the current study of 120 hospitalized noncritically ill SARS-CoV-2 infected patients, we, for the first time, identified that older age and lack of LPV/r treatment were the independent risk factors for prolonged viral shedding. We also found that initial administration of LPV/r treatment within 10 days from symptom onset but not afterward could shorten the duration of SARS-CoV-2 RNA shedding. However, we did not observe the impact of comorbidities and corticosteroid use on the duration of viral shedding.

As an emerging novel coronavirus, data on the duration of SARS-CoV-2 RNA shedding are limited. Previously, we reported the median duration of SARS-CoV-2 RNA shedding was 19.5 days [7] . A recent study including 191 confirmed cases showed that the detectable SARS-CoV-2 RNA sustained for a median of 20 days in survivors and persisted until death in non-survivors [8] . Our corresponding estimate in the current study using throat-swab specimen for viral detection was 23 days. About 30% patients had detectable SARS-CoV-2 RNA after 30 days from symptom onset. Investigations of virus shedding in MERS-CoV and SARS-CoV have demonstrated that viral RNA was detected in the respiratory tract specimen for more than 1 month from illness onset [11, 12] . Lower respiratory tract (LRT) specimens elicited a higher and more prolonged RNA levels than that in upper respiratory tract (URT) specimens [13] . More severely ill patients typically had higher and more prolonged RNA levels [13] . However, the median duration of SARS-CoV-2 RNA shedding did not differ between severe and general patients in the current study. Previous study reported that detectable SARS-CoV-2 RNA can last until death in non-survivors [8, 9] . Whether critically ill patients have more prolonged viral shedding compared to generally or severely ill patients with COVID-19 needs further investigation. To date, studies about the duration of SARS-All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in CoV-2 RNA shedding often used URT specimens for detection [7] [8] [9] . Better elucidation of the kinetics of SARS-CoV-2 replication in the upper and lower respiratory tracts in patients with COVID-19 would be useful in future studies.

Our results demonstrated that older age was independently associated with prolonged SARS-CoV-2 RNA shedding. Previous studies have showed that older age is a risk factor for SARS-CoV-2 infection and has been associated with greater risk of development of acute respiratory distress syndrome and mortality [8, 14] . Our findings further contributed to the literature that older age was also associated with prolonged viral shedding in patients with COVID-19. One possible explanation is that older patients typically generated less robust innate and adaptive immune limiting viral clearance, and then prolonged the duration of viral shedding [15] .

combined with ritonavir to increase drug bioavailability of LPV [16] . LPV/r has been showed to be effective in patients infected with SARS-CoV [17] . LPV/r also improved clinical parameters in MERS-CoV infected marmosets and mice [18, 19] . Our study, for the first time, showed that lack of LPV/R treatment was independently associated with prolonged SARS-CoV-2 RNA shedding in non-critically ill patients with COVID-19.

Administration of LPV/v treatment could shorten the duration of viral shedding compared with no LPV/r treatment. Interestingly, subgroup analysis found that only initial administration of LPV/r treatment within 10 days from symptom onset, but not started after 10 days, could shorten the duration of SARS-CoV-2 RNA shedding compared with no LPV/r treatment. One recent randomized controlled trial showed that LPV/r treatment could not provide additional benefit, including viral shedding, beyond standard care in hospitalized adult patients with severely ill COVID-19 who required a range of ventilatory support mode [8] . However, a post hoc subgroup of the LPV/v in the randomized controlled trial found that earlier administration of antiviral treatment could accelerate clinical recovery and reduce mortality, which is consistent with our findings. Admittedly, patients recruited in the trial were in advanced phase of infection (as evidenced by 25% mortality in the control group). In contrast, most All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 27, 2020. . https://doi.org/10.1101/2020.03.22.20040832 doi: medRxiv preprint patients (99.2%) in our cohort were non-critically ill patients with COVID-19 due to triage strategies. Because LPV/r is not particularly designed against SARS-CoV-2, it is impossible for LPV/r on SARS-CoV-2 to be as effective as neuraminidase inhibitor on influenza [20] . The median duration of viral shedding even in patients who received LPV/r treatment within 10 days from symptom onset was 19 days in current study, demonstrating that LPV/r treatment could not completely inhibit viral replication. In this regard, earlier administration of LPV/r therapy after symptom onset to patients who were not in late phase of infection may be the key things to determine its efficacy. In summary, older age and lack of LPV/r treatment contributed to prolonged SARS-CoV-2 RNA shedding. Earlier administration of LPV/r treatment can shorten the duration of SARS-CoV-2 RNA shedding. Randomized clinical trials to determine the All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Data presented as n (%) or median (IQR) unless otherwise noted. *Data were available for 119 patients a includes congestive heart disease and coronary atherosclerotic heart disease.

All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Data presented as n (%) or median (IQR) unless otherwise noted. a includes congestive heart disease and coronary atherosclerotic heart disease.

All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 27, 2020. . https://doi.org/10.1101/2020.03.22.20040832 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 27, 2020. . https://doi.org/10.1101/2020.03.22.20040832 doi: medRxiv preprint

World Health Organization. Coronavirus disease 2019 (COVID-19): situation report-33

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Clinical characteristics of coronavirus disease 2019 in China

Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore

The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

A trial of Lopinavir-Ritonavir in adults hospitalized with severe COVID-19

Chinese Municipal Health Commission. Chinese management guideline for COVID-19 (version 6.0)

6dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf

Environmental contamination and viral shedding in MERS patients during MERS-CoV outbreak in South Korea

Duration of RT-PCR positivity in severe acute respiratory syndrome

Middle east respiratory syndrome coronavirus transmission

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

The immunopathogenesis of sepsis in elderly patients

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Screening of an FDA-approved compound library identifies four small molecule inhibitors of Middle East Respiratory Syndrome coronavirus replication in cell culture

Treatment with lopinavir/ritonavir or interferon--β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset

Factors associated with prolonged viral shedding in patients with avian influenza A (H7N9) virus infection